Do you have a skin injury that needs a skin graft? Conditions such as:

  • Skin Graft or Auto Graft

  • Cellultis

  • Skin Surgery

  • Skin Infection

  • Surgical Wound Treatment

  • Soft Tissue Injury

  • Scar Revision Requiring Skin Graft

  • Skin Lacerations

  • Degloving Injuries

  • Full Thickness Skin Defects

  • Crush Injury

  • Abdominal Compartment Syndrome

You may be eligible to participate in the new RECELL® System clinical trial.

Pick a State Below to see contact information for this clinical study:
District of Columbia
North Carolina


Contacts and Locations:

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided below.

United States, Arizona
Arizona Burn Center – Valleywise Health Recruiting
Phoenix, Arizona, United States, 85008
Contact: Karen Richey, RN, BSN
Phone: 602-344-5751 Email: [email protected]
Principal Investigator: Kevin N Foster, MD, MBA, FACS

University of Arizona – Banner Health
Tuscon, Arizona, United States, 85719
Contact: Andrea Seach, MPH
Phone: 520-626-2876 Email: [email protected]
Principal Investigator: Lourdes Castanon, MD

United States, California

UCI Medical Center
Orange, California, United States, 92868
Contact: Mia Martinez
Phone: 714-509-2487 Email: [email protected]
Principal Investigator: Theresa L Chin, MD  

United States, District of Columbia

MedStar Washington Hospital Center
Washington, District of Columbia, United States, 20010
Contact: Sarah Burkey
Phone: 202-877-0344 Email: [email protected]
Principal Investigator: Jeffrey Shupp, MD

United States, Florida

Kendall Regional Medical Center
Miami, Florida, United States, 33175
Contact: Brittany Puebla
Phone: 305-480-6694 Email: [email protected]
Principal Investigator: Haaris Mir, MD, FACS

United States, Illinois

Cook County Health
Chicago, Illinois, United States, 60612
Contact: Chitang Joshi
Phone: 312.694.9811 Email: [email protected]

Principal Investigator: Mark A Grevious, MD, MBA, FACS 

United States, Louisiana

University Medical Center
New Orleans, Louisiana, United States, 70112
Contact: Shana Lennard, RN, BSN, OCN, CCRP
Phone: 504-702-5171 Email: [email protected]

Principal Investigator: Herbert Phelan, MD 

United States, North Carolina
Duke University
Durham, North Carolina, United States, 27710
Contact: Jennifer Gallagher
Phone: 540-905-0355 Email: [email protected]
Principal Investigator: David A Brown, MD, PhD


Wake Forest University Health Sciences Recruiting
Winston-Salem, North Carolina, United States, 27157
Contact: Renea Jennings, RN, BSN
Phone: 336-716-6709 Email: [email protected]
Contact: Caleb Suggs
Phone: 336-713-4339 Email: [email protected]
Principal Investigator: Joseph A Molnar, MD, PhD


United States, Ohio

Ohio State University
Columbus, Ohio, United States, 43210
Contact: Kathryn Schubauer
Phone: 614-293-4472 Email: [email protected]
Principal Investigator: Alfredo Cordova, MD


United States, Pennsylvania

Temple University
Philadelphia, Pennsylvania, United States, 19140
Contact: Andrea Van Zandt, BA 
Phone: 215-707-5915 Email: [email protected]
Principal Investigator: Lisa Rae, MD, FACS

University of Pittsburgh Medical Center Recruiting
Pittsburgh, Pennsylvania, United States, 15213
Contact: Eleanor Shirley, MA
Phone: 412-383-7712 Email: [email protected]
Principal Investigator: J. Peter Rubin, MD, FACS


United States, Texas


Driscoll Children’s Hospital
Corpus Christi, Texas, United States, 78411
Contact: Erin Richmond, MS, RN, CPHON, CCRP
Phone: 361-694-5978 Email: [email protected]
Principal Investigator: Kevin Hopkins, MD, FACS 


JPS Health Network Recruiting
Fort Worth, Texas, United States, 76104
Contact: Valentina Jovic
Phone: 817-702-1680 Email: [email protected]
Principal Investigator: Steven E Mapula, MD


Metis Foundation
San Antonio, Texas, United States, 78216
Contact: Victoria Hatem, RN
Phone: 210-488-4651 Email: [email protected]
Principal Investigator: Rodney K Chan, MD 

Eligibility Criteria:

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided above.

Inclusion Criteria:

  1. The patient requires autografting for treatment of an acute full-thickness skin defect (e.g., trauma- or surgery-related).
  2. The maximum area requiring autografting is 50% Total Body Surface Area (TBSA).
  3. Two comparable areas requiring autografting, each at least 80 cm2 (or 160 cm2 contiguous), excluding face and genitalia. When hands or joints are included in the treatment areas, comparability of treatment areas means that each area (RECELL and Control) must include the same contralateral joint and/or hand.
  4. The patient is at least 5 years of age.
  5. The patient (or parent/guardian) is willing and able to comply with all compulsory study procedures and visit schedule.
  6. The patient agrees to abstain from any other treatment (e.g., external fixation) of the study treatment areas for the duration of his/her participation the study (1 year).
  7. The patient agrees to abstain from enrollment in any other interventional clinical trial for the duration of his/her participation the study (1 year).
  8. In the opinion of the investigator, the patient and/or guardian must be able to:
    1. Understand the full nature and purpose of the study, including possible risks and adverse events,
    2. Understand instructions, and
    3. Provide voluntary informed written consent.

Exclusion Criteria:

  1. Not able to understand English or Spanish.
  2. The area requiring autografting sustained a burn injury.
  3. The treatment area has previously failed to heal subsequent to surgical intervention for closure.
  4. The patient is unable to follow the protocol requirements.
  5. The patient has a condition that in the investigator’s opinion may compromise patient safety or trial objectives.
  6. Current use of medications that in the investigator’s opinion may compromise patient safety or trial objectives.
  7. The patient has a known hypersensitivity to trypsin or compound sodium lactate for irrigation (Hartmann’s) solution.
  8. The patient is pregnant or breast-feeding (pregnancy test should be performed in accordance with local institutional requirements).
  9. Life expectancy is less than 1 year.
This website stores cookies on your computer. These cookies are used to improve your website experience and provide more personalized services to you, both on this website and through other media. To find out more about the cookies we use, see our privacy policy.